A Study to Determine the Safety and Efficacy of NT-501 With M-CHFM
A Multicenter Study to Determine the Safety and Efficacy of NT-501 Utilizing the Medica Membrane in Macular Telangiectasia Type 2 (MacTel), Including a Randomized Comparative Expansion Cohort
The overall purpose of this global, multicenter, two cohort, central image evaluator masked study is to characterize the clinical safety and efficacy of NT-501 manufactured using the Medica - Clinical Hollow Fiber Membrane (M-CHFM) for the treatment of MacTel and to evaluate whether its safety profile and efficacy are comparable to those of NT-501 manufactured using the Clinical Hollow Fiber Membrane (CHFM).
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This Phase 3 study consists of two cohorts:
- Cohort 1 (Extension): Includes participants previously enrolled under the original protocol who received NT-501 (M-CHFM) and will continue follow-up. Participants will undergo evaluations of safety and efficacy from pre-surgery through month 24 or in the event of NT-501 explantation for any reason.
- Cohort 2 (Expansion): Includes newly enrolled participants randomized 1:1 to receive either NT-501 (M-CHFM) or NT-501 (CHFM). Participants will undergo evaluations of safety and efficacy from pre-surgery through month 12 or in the event of NT-501 explantation for any reason.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Patricia Davis
- 전화번호: 401-333-3880
- 이메일: p.davis@neurotechusa.com
연구 장소
-
-
California
-
Walnut Creek, California, 미국, 94598
- 모집하지 않고 적극적으로
- Bay Area Retina Associates, A Medical Group
-
-
Michigan
-
Grand Rapids, Michigan, 미국, 49546
- 모집하지 않고 적극적으로
- Foundation for Vision Research
-
-
Texas
-
Bellaire, Texas, 미국, 77401
- 모집하지 않고 적극적으로
- Retina Consultants of Texas
-
-
-
-
-
East Melbourne, 호주
- 아직 모집하지 않음
- Cerulea
-
연락하다:
- Thuy Chau
- 이메일: tchau@ceruleaclinicaltrials.org.au
-
수석 연구원:
- Penelope Allen, MD
-
Perth, 호주
- 모병
- Lion's Eye Institute
-
연락하다:
- Diana Bowman
- 이메일: diana.bowman@lei.org.au
-
수석 연구원:
- Ian Constable, MD
-
Sydney, 호주
- 아직 모집하지 않음
- Sydney Eye Hospital
-
연락하다:
- Emily Luu
- 이메일: emily.luu@sydney.edu.au
-
수석 연구원:
- Elisa Cornish, MD
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria
To participate in this study, the potential subject and at least 1 of their eyes must meet all of the following criteria:
- Subjects must have a positive diagnosis of MacTel with evidence of fluorescein leakage typical of MacTel and at least one of the other features that include hyperpigmentation that is outside of a 500-micron radius from the center of the fovea, retinal opacification, crystalline deposits, right-angle vessels, or inner/outer lamellar cavities seen clinically or on SD-OCT.
- Subject must have a break in the ellipsoid zone (EZ) (area of IS/OS loss) as measured by SD-OCT between 0.16 and 2.00 millimeters squared.
- Subject's best-corrected visual acuity (BCVA) is 54-letter score or better (20/80 or better) as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at screening.
- Subject must have steady fixation in the foveal or parafoveal area and sufficiently clear media for good quality retinal imaging.
- Subject must be greater than or equal to 21 years of age and less than 80 years of age at screening.
- Subject or their legally authorized representative must be able to provide written informed consent to participate in the study, in accordance with the International Conference on Harmonisation Good Clinical Practices guidelines, and local regulations, before initiating any study-related procedures.
Exclusion Criteria
To participate in this study, the potential subject must not meet any of the following criteria. The ocular exclusion criteria are related to the study eye (unless indicated for either eye):
- Subject is medically unable to comply with study procedures or follow-up visits.
- Subject received intravitreal steroid therapy for non-neovascular MacTel within the last 3 months.
- Subject has ever received intravitreal anti-vascular endothelial growth factor (VEGF) therapy in the study eye OR has, within the past 3 months, received intravitreal anti-VEGF therapy in the fellow eye at randomization.
- Subject has evidence of ocular disease other than MacTel that, in the judgment of the examining physician, may confound the diagnosis, procedures, or outcome of the study (e.g., uncontrolled glaucoma, severe non-proliferative or proliferative diabetic retinopathy, uveitis).
- Subject has a chronic requirement (e.g., ≥ 4 weeks at a time) for ocular medications and/or has a diagnosed disease that, in the judgment of the examining physician, may be vision threatening or may affect the primary outcome (artificial tears are permitted). The exceptions to this exclusion criteria include artificial tears or one glaucoma medication for early or intermediate primary open-angle glaucoma.
- Subject has evidence of intraretinal neovascularization or subretinal neovascularization (SRNV), as evidenced by hemorrhage, hard exudate, subretinal fluid or intraretinal fluid in either eye.
- Subject has evidence of intraretinal hyperreflectivity by OCT.
- Subject has evidence of central serous chorio-retinopathy in either eye.
- Subject has evidence of pathologic myopia in either eye.
- Subject has significant corneal or media opacities in either eye.
- Subject has had a vitrectomy, penetrating keratoplasty, trabeculectomy, or trabeculoplasty.
- Subject has any of the following lens opacities: cortical opacity > standard 3, posterior subcapsular opacity > standard 2, or a nuclear opacity > standard 3 as measured on the Age -Related Eye Disease Study (AREDS) clinical lens grading system.
- Subject has undergone lens removal in the previous 3 months or YAG laser within 4 weeks.
- Previous participation in any Neurotech MacTel clinical trial unless the participant: (1) previously consented and screened for a MacTel study but was a screen failure solely due to insufficient lesion size; or (2) has completed participation in the prior Neurotech MacTel study, is not actively enrolled in another Neurotech MacTel study, and has an eligible study eye that was not the study eye in the previous trial.
- Subject was a participant in any other ocular related or ocular impacted clinical trial of an intervention (drug or device) within the last 6 months.
- Subject is on chemotherapy.
- Subject is pregnant or breastfeeding.
- Subject has a history of malignancy that would compromise the 12-month study survival.
- Subject with a history of ocular herpes virus in either eye.
- Subject has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations, and outcome assessments.
- Subject has evidence of subfoveal RPE hyperplasia.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Cohort 1 (Extension) - M-CHFM
Previously enrolled Cohort 1 participants received M-CHFM and will undergo evaluations of safety and efficacy from pre-surgery through month 24 or in the event of NT-501 explantation for any reason. |
Single implantation of NT-501 manufactured using the Medica - Clinical Hollow Fiber Membrane (M-CHFM) |
|
실험적: Cohort 2 (Expansion) - M-CHFM
Participants are randomized 1:1 to receive M-CHFM. Participants will undergo evaluations of safety and efficacy from pre-surgery through month 12 or in the event of NT-501 explantation for any reason. |
Single implantation of NT-501 manufactured using the Medica - Clinical Hollow Fiber Membrane (M-CHFM) |
|
활성 비교기: Cohort 2 (Expansion) - CHFM
Participants are randomized 1:1 to receive CHFM (US commercially available ENCELTO). Participants will undergo evaluations of safety and efficacy from pre-surgery through month 12 or in the event of NT-501 explantation for any reason. |
Single implantation of NT-501 manufactured using the Clinical Hollow Fiber Membrane (CHFM)
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Cohort 1 (Extension) - Efficacy
기간: Baseline to 24 months
|
Rate of change in EZ area loss as measured by en face imaging by Spectral-Domain Optical Coherence Tomography (SD-OCT) in the study eye of NT-501 in participants who received NT-501 with M-CHFM |
Baseline to 24 months
|
|
Cohort 2 (Expansion) - Efficacy
기간: Baseline to 12 months
|
Rate of change in EZ area loss as measured by en face imaging by Spectral-Domain Optical Coherence Tomography (SD-OCT) in the study eye of NT-501 in participants who received NT-501 with M-CHFM as compared to NT-501 with CHFM |
Baseline to 12 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Cohort 1 (Extension) - Safety
기간: Baseline to 24 months
|
Incidence of ocular and non-ocular adverse events (AEs) and serious adverse events (SAEs) |
Baseline to 24 months
|
|
Cohort 2 (Expansion) - Safety
기간: Baseline to 12 months
|
Incidence of ocular and non-ocular adverse events (AEs) and serious adverse events (SAEs) |
Baseline to 12 months
|
|
Cohort 1 (Extension) - Best Corrected Visual Acuity
기간: Baseline to 24 months
|
Percentage of participants with a loss of 15 letters or more in best-corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study (ETDRS) distance chart |
Baseline to 24 months
|
|
Cohort 2 (Expansion) - Best Corrected Visual Acuity
기간: Baseline to 12 months
|
Percentage of participants with a loss of 15 letters or more in best-corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study (ETDRS) distance chart |
Baseline to 12 months
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Cohort 1 (Extension) - Aqueous CNTF
기간: Month 12 - Month 24
|
Either a binary result (present/absent) for measurable CNTF or actual CNTF concentration |
Month 12 - Month 24
|
|
Cohort 2 (Expansion) - Aqueous CNTF
기간: Baseline to 12 months
|
Either a binary result (present/absent) for measurable CNTF or actual CNTF concentration |
Baseline to 12 months
|
공동 작업자 및 조사자
수사관
수사관
- 연구 의자: Thomas Aaberg, Jr., MD, Neurotech Pharmaceuticals
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- NTMT-03C
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .